Cancer vaccines: the next immunotherapy frontier
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2022/08/23
-
Journal
-
Indian UGC (journal)
-
Refrences179
-
Citations218
-
Matthew J. Lin ORCID (unauthenticated)
-
Judit Svensson-Arvelund
-
Gabrielle S. Lubitz ORCID (unauthenticated)
-
Aurélien Marabelle
-
Ignacio Melero ORCID (unauthenticated)
-
Brian D. Brown ORCID (unauthenticated)
-
Joshua D. Brody ORCID (unauthenticated)
Cite
Lin, Matthew J., et al. “Cancer Vaccines: The Next Immunotherapy Frontier”. Nature Cancer, vol. 3, no. 8, 2022, pp. 911-26, https://doi.org/10.1038/s43018-022-00418-6.
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022). Cancer vaccines: the next immunotherapy frontier. Nature Cancer, 3(8), 911-926. https://doi.org/10.1038/s43018-022-00418-6
Lin, Matthew J., Judit Svensson-Arvelund, Gabrielle S. Lubitz, Aurélien Marabelle, Ignacio Melero, Brian D. Brown, and Joshua D. Brody. “Cancer Vaccines: The Next Immunotherapy Frontier”. Nature Cancer 3, no. 8 (2022): 911-26. https://doi.org/10.1038/s43018-022-00418-6.
Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, et al. Cancer vaccines: the next immunotherapy frontier. Nature Cancer. 2022;3(8):911-26.
Journal Categories
Medicine
Internal medicine
Neoplasms
Tumors
Oncology
Including cancer and carcinogens
Medicine
Medicine (General)
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma | Nature |
| 209 | 2021 |
| Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors | Cell |
| 68 | 2021 |
| 10.1158/1538-7445.AM2021-CT002 | Cancer Research |
| 2021 | |
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma | Nature Medicine |
| 84 | 2021 |
| Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma | Nature Medicine |
| 231 | 2021 |
Refrences Analysis
The category
Medicine: Medicine (General) 72
is the most frequently represented among the references in this article. It primarily includes studies from Journal for ImmunoTherapy of Cancer and Nature. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Self‐Generating Gold Nanocatalysts in Autologous Tumor Cells for Targeted Catalytic Immunotherapy | Advanced Healthcare Materials |
| 2024 | |
Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy | Advanced Healthcare Materials |
| 2024 | |
Supramolecular Lipid Nanoparticles Based on Host–Guest Recognition: A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy | Advanced Materials |
| 2024 | |
Sustained‐Release of Antigens and CpG‐DNA using Temperature‐Responsive Biodegradable Injectable Polymers: Performance on Induction of Immune Responses | Advanced Therapeutics |
| 2024 | |
Enhanced Photodynamic Therapy Synergizing with Inhibition of Tumor Neutrophil Ferroptosis Boosts Anti‐PD‐1 Therapy of Gastric Cancer | Advanced Science |
| 2024 |
Citations Analysis
The category
Medicine: Medicine (General) 59
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled The cGAS–STING pathway and cancer and was published in 2022. The most recent citation comes from a 2024 study titled Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion. This article reached its peak citation in 2023, with 127 citations. It has been cited in 136 different journals, 30% of which are open access. Among related journals, the Frontiers in Immunology cited this research the most, with 11 citations. The chart below illustrates the annual citation trends for this article.